文献速递淋巴瘤造血干细胞移植与细胞治疗

利妥昔单抗/苯达莫司汀联合利妥昔单抗/阿糖胞苷诱导治疗适合移植的套细胞淋巴瘤

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

该汇总分析整合2项2期试验及1项脱组队列,评估3周期RB与3周期RC序贯或交替诱导后行ASCT在初治适合移植MCL患者中的疗效。88例中92%完成诱导、84%接受ASCT,诱导末总缓解率97%、完全缓解率90%,中位随访33个月时3年PFS 83%、OS 92%。

要点

  • RB/RC诱导后ASCT在适合移植初治MCL中获高缓解率与持久缓解。
  • 诱导末总缓解率97%、完全缓解率90%,3年PFS 83%、OS 92%。
  • 试验患者3/4级不良事件以淋巴细胞减少88%、血小板减少85%、中性粒细胞减少83%为主。

核心结论

  • RB/RC序贯或交替诱导后行ASCT在适合移植的初治MCL患者中实现高比例持久缓解。

研究设计与样本

  • 汇总分析2项2期试验(DFCI试验23例、WUSTL试验18例)及DFCI脱组队列47例,共88例初治适合移植MCL患者接受3周期RB与3周期RC后行ASCT。
  • DFCI试验采用序贯RB/RC,WUSTL试验采用交替RB/RC;DFCI试验评估MRD。

主要发现

  • 88例中92%完成诱导,84%接受计划的巩固性ASCT。
  • 87例可评估疗效者诱导末总缓解率97%、完全缓解率90%。
  • 中位随访33个月,3年无进展生存率83%、总生存率92%。
  • 试验患者3/4级不良事件包括淋巴细胞减少88%、血小板减少85%、中性粒细胞减少83%、发热性中性粒细胞减少15%。
  • 诱导期无治疗相关死亡,ASCT后发生2例治疗相关死亡;接受MRD检测者ASCT后持续MRD阴性,仅1例出现MRD后复发。

临床怎么用

  • 对适合移植的初治MCL患者,可考虑RB/RC诱导后行ASCT以获得高缓解率和持久缓解。

局限性

  • 本文为2项2期试验与脱组队列的汇总分析,非随机对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The addition of high-dose cytarabine to rituximab/bendamustine (RB) induction could improve outcomes for transplant-eligible patients with mantle cell lymphoma (MCL). We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab/high-dose cytarabine (RC) followed by autologous stem cell transplantation (ASCT) among untreated, transplant-eligible patients with MCL. Dana-Farber Cancer Institute (DFCI) and Washington University in St. Louis (WUSTL) led separate phase 2 trials testing sequential and alternating cycles of RB/RC, respectively. Patients treated at DFCI with sequential RB/RC off trial were retrospectively identified. Minimal residual disease (MRD) was assessed in the DFCI trial. A total of 88 patients (23 DFCI trial, 18 WUSTL trial, and 47 off trial) received RB/RC; 92% of patients completed induction, and 84% underwent planned consolidative ASCT. Grade 3 or 4 adverse events among trial patients included lymphopenia (88%), thrombocytopenia (85%), neutropenia (83%), and febrile neutropenia (15%). There were no treatment-related deaths during induction and 2 following ASCT. Among 87 response-evaluable patients, the end-of-induction overall and complete response rates were 97% and 90%, respectively. After a median follow-up of 33 months, 3-year progression-free survival and overall survival were 83% and 92%, respectively. Patients undergoing MRD testing experienced prolonged MRD negativity after ASCT with emergence of MRD occurring in only 1 patient who subsequently relapsed. RB/RC followed by ASCT achieves high rates of durable remissions in transplant-eligible patients with MCL. These trials were registered at www.clinicaltrials.gov as #NCT01661881 (DFCI trial) and #NCT02728531 (WUSTL trial).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020. PMID: 32126141. doi:10.1182/bloodadvances.2019001355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。